+

WO2004053064A3 - Fragment fab' génétiquement modifié anti-facteur de nécrose tumorale alpha combiné à des médicaments antirhumatismaux modifiant l'évolution de la maladie - Google Patents

Fragment fab' génétiquement modifié anti-facteur de nécrose tumorale alpha combiné à des médicaments antirhumatismaux modifiant l'évolution de la maladie Download PDF

Info

Publication number
WO2004053064A3
WO2004053064A3 PCT/US2003/038499 US0338499W WO2004053064A3 WO 2004053064 A3 WO2004053064 A3 WO 2004053064A3 US 0338499 W US0338499 W US 0338499W WO 2004053064 A3 WO2004053064 A3 WO 2004053064A3
Authority
WO
WIPO (PCT)
Prior art keywords
necrosis factor
tumor necrosis
disease
factor alpha
combination
Prior art date
Application number
PCT/US2003/038499
Other languages
English (en)
Other versions
WO2004053064A2 (fr
Inventor
Susan L Woulfe
Rita Jain
Aimee Burr
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Priority to AU2003293366A priority Critical patent/AU2003293366A1/en
Publication of WO2004053064A2 publication Critical patent/WO2004053064A2/fr
Publication of WO2004053064A3 publication Critical patent/WO2004053064A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition thérapeutique combinée destinée à moduler, traiter et/ou prévenir les maladies inflammatoires. La composition thérapeutique de l'invention comprend un fragment Fab' d'anticorps CDP870 qui est spécifique des déterminants antigéniques du facteur de nécrose tumorale alpha, et au moins un médicament modifiant l'évolution de la maladie rhumatismale (DMARD) tel que le méthotrexate ou la sulfasalazine. La composition thérapeutique de l'invention peut être administrée à un sujet humain ou animal en une dose unique ou en de multiples doses sur une période de temps pour traiter l'arthrite rhumatoïde, la maladie de Crohn ou une quelconque autre maladie inflammatoire.
PCT/US2003/038499 2002-12-05 2003-12-05 Fragment fab' génétiquement modifié anti-facteur de nécrose tumorale alpha combiné à des médicaments antirhumatismaux modifiant l'évolution de la maladie WO2004053064A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003293366A AU2003293366A1 (en) 2002-12-05 2003-12-05 Engineered fab'fragment anti-tumor necrosis factor alpha in combination with disease modifying anti-rheumatic drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43105302P 2002-12-05 2002-12-05
US60/431,053 2002-12-05

Publications (2)

Publication Number Publication Date
WO2004053064A2 WO2004053064A2 (fr) 2004-06-24
WO2004053064A3 true WO2004053064A3 (fr) 2005-07-07

Family

ID=32507667

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/038499 WO2004053064A2 (fr) 2002-12-05 2003-12-05 Fragment fab' génétiquement modifié anti-facteur de nécrose tumorale alpha combiné à des médicaments antirhumatismaux modifiant l'évolution de la maladie

Country Status (3)

Country Link
US (1) US20050042219A1 (fr)
AU (1) AU2003293366A1 (fr)
WO (1) WO2004053064A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
US20050181479A1 (en) * 2005-03-04 2005-08-18 Medimmune, Inc. Periplasmic expression of antibodies using a single signal sequence
US20080173093A1 (en) * 2007-01-18 2008-07-24 The Regents Of The University Of Michigan System and method for photoacoustic tomography of joints
CN104862328A (zh) * 2014-02-26 2015-08-26 上海美迪西生物医药有限公司 重组阿达木单抗Fab片段在大肠杆菌中的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455275B1 (en) * 1980-02-25 2002-09-24 The Trustees Of Columbia University In The City Of New York DNA construct for producing proteinaceous materials in eucaryotic cells
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5741488A (en) * 1992-10-08 1998-04-21 The Kennedy Institute For Rheumatology Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHOY ET AL: "Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial", RHEUMATOLOGY, vol. 41, 2002, pages 1133 - 1137, XP002333059, DOI: doi:10.1093/rheumatology/41.10.1133 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis

Also Published As

Publication number Publication date
WO2004053064A2 (fr) 2004-06-24
AU2003293366A1 (en) 2004-06-30
US20050042219A1 (en) 2005-02-24
AU2003293366A8 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
HUS1600042I1 (hu) Anti-CS1 antitestek terápiás alkalmazása
NZ596878A (en) Methods of administering anti-tnfalpha antibodies
JP2004501101A5 (fr)
NZ591362A (en) Multiple-variable dose regimen for treating tnfa-related disorders
IL178121A0 (en) Therapeutic use of anti-cs1 antibodies
JP2002535285A5 (fr)
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
AR040603A1 (es) El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
RU96101193A (ru) Фрагменты антител в терапии
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
MXPA05012810A (es) Formas de dosis oral de memantina.
WO2003054018A3 (fr) Anticorps anti-tirc7 servant au traitement de maladies inflammatoires
WO2004053064A3 (fr) Fragment fab' génétiquement modifié anti-facteur de nécrose tumorale alpha combiné à des médicaments antirhumatismaux modifiant l'évolution de la maladie
DE602004024221D1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen
EP0795332A3 (fr) Utilisation médicale de gamma interféron dans les maladies pulmonaires interstitielles
WO2003097082A3 (fr) Traitement de la maladie de crohn ou du psoriasis a partir d'anticorps anti-interferon gamma
RU2002103808A (ru) Способ лечения болевого синдрома у онкологических больных
WO2005087255A3 (fr) Procede d'optimisation de traitement avec l'interferon -tau
WO2003082916A3 (fr) Antigenes associes a une tumeur
RU2003110183A (ru) Способ лечения рассеянного склероза
Bagel Evaluating the interleukin antibodies
WO2003032895A3 (fr) Methodes et compositions pharmaceutiques destinees a la stimulation du systeme immunitaire et/ou au traitement du cancer
SSADOVSKY Algorithm for subcutaneous heparin treatment of DVT.
WO2002008421A1 (fr) Nouveau polypeptide, recepteur humain 21.45 du facteur de la necrose tumorale, et polynucleotide codant ce polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载